Stifel Nicolaus reiterates its Buy rating on Lexicon Pharmaceuticals LXRX with a price target that is raised from $3 to $4.
Stifel Nicolaus notes, "Management intends to move the once-daily (QD) 400mg dose forward into P3 development – a decision we fully support given the meaningfully greater HbA1c reduction and totality of secondary efficacy data suggesting increasing efficacy at this dose level is not related to urinary glucose excretion (UGE) alone. Statistically significant reductions in both body weight and systolic blood pressure – two poorly controlled co-morbidities in this patient population – were also observed at daily dose exposures >200mg."
LXRX closed at $1.95 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsBiotechnologyHealth CareStifel Nicolaus
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in